Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

ADAPY holding history

Adaptimmune Therapeutics PLC in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

ADAPY overviewAll 13F holders of ADAPYFull Q2 2026 holdings

Shares (Q4 2025)
0
Sold out in Q4 2025
Value
$0
% of portfolio
0.0%
Quarters held
19
Since Q1 2021
Holdings of ADAPY by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q4 20250$00.0%−6,667,358−100.0%Sold outHolders
Q3 20256,667,358$866.8K<0.1%+6,604,400+10,490.2%AddedHolders
Q2 202562,958$15.1K<0.1%−949,782−93.8%ReducedHolders
Q1 20251,012,740$199.5K<0.1%+870,996+614.5%AddedHolders
Q4 2024141,744$76.4K<0.1%+139,927+7,701.0%AddedHolders
Q3 20241,817$1.73K<0.1%00.0%UnchangedHolders
Q2 20241,817$1.77K<0.1%−194,879−99.1%ReducedHolders
Q1 2024196,696$310.8K<0.1%+172,003+696.6%AddedHolders
Q4 202324,693$19.6K<0.1%−3,641−12.9%ReducedHolders
Q3 202328,334$22.1K<0.1%−2,646−8.5%ReducedHolders
Q2 202330,980$28.7K<0.1%+4,230+15.8%AddedHolders
Q1 202326,750$29.2K<0.1%+3,125+13.2%AddedHolders
Q4 202223,625$34.5K<0.1%+21,641+1,090.8%AddedHolders
Q3 20221,984$2.00K<0.1%−2,720−57.8%ReducedHolders
Q2 20224,704$8.00K<0.1%−788−14.3%ReducedHolders
Q1 20225,492$12.0K<0.1%−11,080−66.9%ReducedHolders
Q4 202116,572$61.0K<0.1%+1,067+6.9%AddedHolders
Q3 202115,505$80.0K<0.1%+1,593+11.5%AddedHolders
Q2 202113,912$60.0K<0.1%−174,172−92.6%ReducedHolders
Q1 2021188,084$998.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.